Sino Biopharmaceutical Sells 84.2% Stake in Shanghai CP General Pharmaceutical
China-based biotech company Sino Biopharmaceutical Ltd (HKG: 1177) has announced the sale of an 84.2%...
Company
Jiangsu QYuns Therapeutics Plans IPO on Hong Kong Stock Exchange
China-based Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509) has announced its intention to pursue an...
Janssen Unveils Promising Clinical Data on IL-23 Blockers for Psoriasis
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) is showcasing new clinical data...
MicroPort Secures Market Approvals for ULYS ICDs and INVICTA Leads in Japan
Shanghai-based MicroPort Scientific Corp. (HKG: 0853) has announced that its France-based subsidiary, MicroPort Cardiac Rhythm...
Bayer Opens First Cell Therapy Production Facility in the U.S. to Advance Research
Bayer AG (ETR: BAYN) has inaugurated its first production site dedicated to cell therapies, marking...
AstraZeneca Seeks Approval for Capivasertib in Combination with Faslodex for Breast Cancer Treatment
AstraZeneca (AZ, NASDAQ: AZN) has submitted a market approval filing for its Category 1 drug...
Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval for Anti-Tumor Drug Candidate SHR-2022
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
China NT Pharma Group Enters MOU with Global Fund to Expand Orthopedic Product Line
China NT Pharma Group Company Ltd (HKG: 1011), a China-based pharmaceutical company, has announced the...
BioCity Biopharma Partners with AstraZeneca for Phase Ib/II Study in Hepatocellular Carcinoma
China-based biotech firm BioCity Biopharma has entered into a clinical study partnership with UK pharmaceutical...
Shanghai Shende Wuchuang Secures $28 Million in Series D Financing for Medical Device Innovation
Shanghai Shende Wuchuang Times Medical Technology Co., Ltd has reportedly secured nearly RMB 200 million...
Atom Bioscience Initiates Global Phase III Clinical Study for Gout Drug ABP-671
China-based Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd) has announced the enrollment of...
GluBio Pharmaceutical’s GLB-002 Receives NMPA Approval for Clinical Trials in Hematological Tumors
GluBio Pharmaceutical Co., Ltd, a specialist in molecular glue targeted protein degradation (TPD) based in...
Med Vision’s Sleep Disorder Software Receives Category II Approval in China
Hangzhou-based Med Vision, a provider of virtual reality (VR)-enabled digital therapeutics (DTx) solutions, has reportedly...
Luye Pharma Files NDA for Paliperidone Palmitate Injectable Suspension with US FDA
China-based Luye Pharma Group (HKG: 2186) has announced the submission of a New Drug Application...
Apeloa Pharmaceutical Expands Global Footprint with Apeloa Europe GmbH in Germany
China-based contract development and manufacturing organization (CDMO) Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has announced...
AbbVie Acquires Mitokinin, Advancing PINK1 Activator for Parkinson’s Disease
AbbVie (NYSE: ABBV) has announced the acquisition of US-based biotechnology company Mitokinin, exercising an exclusive...
Shanghai BDgene’s BD112 Earns Orphan Drug Designation from US FDA for Huntington’s Disease
Shanghai BDgene Technology Co., Ltd, a specialist in gene therapy, has announced that its drug...
AstraZeneca Alum Yu Yuping Appointed Vice-President at Merck KGaA’s China Unit
Yu Yuping, a seasoned professional with a distinguished career at AstraZeneca (AZ, NASDAQ: AZN), has...
AffaMed Technologies Secures Exclusive Rights to SIFI’s Intraocular Lens Products in Greater China
AffaMed Technologies, a joint venture between China’s AffaMed Therapeutics and Italy-based SIFI S.p.A., has announced...
Simcere Pharmaceutical Secures Exclusive Rights to AnDiCon’s Anti-Influenza Candidate ADC189
China-based Simcere Pharmaceutical Group (HKG: 2096) has announced a strategic collaboration agreement with domestic firm...